Prognostic Value of CD200 in Hematological Malignancies. Hematological Malignancies Comprise a Group of Malignant Clonal Disorders Arising From the Hematopoietic Tissues , Including Leukemia , Multiple Myeloma , and They Have a High Morbidity and Mortality

Resident of Clinical Pathology in Sohag Oncology Center

Status

Not yet recruiting

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT06258629

Enrollment

Registered

2024-02-14

Start date

2024-02-15

Completion date

2025-02-06

Last updated

2024-02-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hematological Malignancies

Brief summary

Prognostic value of 'CD200' in hematological malignancies Hematological malignancies comprise a group of malignant clonal disorders arising from the hematopoietic tissues , including leukemia , multiple myeloma , and lymphoma , and they have a high morbidity and mortality

Interventions

DIAGNOSTIC_TESTFlowcytometry on bone marrow aspiration

Flowcytometry on bone marrow aspiration

Study design

Observational model

CASE_CONTROL

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

1 Years to 60 Years

Inclusion criteria

* Newly diagnosed cases of hematological malignancis.

Exclusion criteria

* Known cases of hematological malignancies and on treatment.

Design outcomes

Primary

Measure	Time frame	Description
Level of CD200 diagnostic marker assessed by flow cytometry	one year	Prognostic value of CD200 in hematological malignancies

Contacts

Primary ContactReem ya Hashim, resident

reem011091@med.sohag.edu.eg01285481488

Backup Contactsherine Ph aziz, resident

01227848855

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026